A
while we can have a punt at answering your question about costs to approval... Avexa can not, atm, answer your question...
Mr Drona has seen fit not to revisit the FDA to clarify the 'faster' path to market promised following announcement of the closure of the phiii...
he has the data, with some impressive numbers, but has decided not to bother clarifying the path to market for this fda fast-track approved drug...
an answer from the fda should be cheap and quick... and provide some clarity for Avexa and partners...
strange indeed Mr Drona...why havent u?
you make Mr Lee look good...!
DRONA MUST GO
dronas unanimous decisions!, page-11
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)